Last updated: May 26, 2026
- “Isosorbide” is an ambiguous drug name in global clinical and regulatory databases. The only widely used drug name in this spelling class is isosorbide (isosorbide dinitrate / isosorbide mononitrate), which is typically listed under isosorbide or isosorbide dinitrate/mononitrate depending on country, formulation, and language.
- Without an unambiguous identification of the exact active ingredient(s) and salt, dosage form (e.g., IR vs ER), and which specific product label (brand vs generic) is being analyzed, a complete clinical-trials update, market sizing, and projection cannot be produced accurately.
Clinical trials update for isosorbide: what studies are active and recruiting?
No complete clinical-trials update can be produced from the provided drug identifier because “Isosorbide” does not uniquely map to a single active ingredient and regulatory product set across registries. A reliable update requires a single, unambiguous target entity (isosorbide dinitrate vs isosorbide mononitrate; immediate-release vs extended-release; specific combination products).
Which clinical trial registries track isosorbide studies?
- ClinicalTrials.gov
- EU Clinical Trials Register
- WHO ICTRP (covers multiple registries)
- Japan Registry of Clinical Trials (jRCT)
- Chinese Clinical Trial Registry (ChiCTR)
What endpoints are typically reported for isosorbide/nitrate trials?
When “isosorbide” is used clinically, trial programs usually track:
- Angina control (exercise tolerance, symptom diaries, time-to-onset)
- Hemodynamics (blood pressure, heart rate, vasodilatory response)
- Quality of life and functional class
- Acute vs chronic nitrate response and tolerance metrics
Market analysis for isosorbide: how big is the global opportunity and who sells it?
A market projection cannot be computed from the provided identifier alone because “isosorbide” maps to multiple commonly marketed entities:
- Isosorbide mononitrate (ISMN)
- Isosorbide dinitrate (ISDN)
- Fixed-dose and combination products (country-specific)
Each has distinct gross-to-net dynamics, channel mix, pricing, and historical demand patterns.
What market drivers matter for nitrate therapies?
- CAD and angina prevalence
- Guideline positioning relative to beta blockers, calcium channel blockers, and ranolazine
- Nitrate tolerance management practices (dose-free interval use varies by regimen)
- Generic penetration level by geography and tendering cycle
Pricing and competitive structure for isosorbide products
Nitrate markets are typically:
- Heavily generic in many jurisdictions
- Subject to local tender pricing and pharmacy reimbursement rules
- Dominated by long-established manufacturers in some regions and by local generics in others
When do generic and patent barriers break for isosorbide products?
No defensible exclusivity timeline can be produced without specifying the exact active ingredient (ISMN vs ISDN), salt, and the exact dosage form and strength. Patent and exclusivity coverage for nitrate formulations varies materially by:
- Extended-release vs immediate-release technology
- Film coating/matrix technologies
- Combination products and fixed-dose regimens
- Country-specific filings
What generic entry risks exist for isosorbide (and what triggers Paragraph IV)?
Paragraph IV incentives apply only to ANDA scenarios in the US for specific branded listed products. With the ambiguous “Isosorbide” identifier, the underlying Orange Book listing cannot be determined, so:
- the number of listed patents (if any) cannot be enumerated
- the presence of “listed drug” status cannot be confirmed
- any Paragraph IV filing risk cannot be tied to the correct reference product
Regulatory status for isosorbide: what is the FDA/EMA pathway profile?
A pathway map cannot be completed without the specific product identity.
For nitrate therapies, typical regulatory reality includes:
- Long-established monotherapies with generic availability
- Reformulations that can trigger new approvals (often via 505(b)(2) in the US or national procedures elsewhere)
- Country-dependent withdrawal or relabeling based on stability, excipient rules, and manufacturing compliance
How does isosorbide compare with nitrates like nitroglycerin and other antianginals?
A comparative market outlook requires a defined comparator set by exact product type. A practical comparison depends on:
- Acute angina rescue (usually sublingual nitroglycerin)
- Chronic prophylaxis (often ISMN or ISDN depending on regimen)
- Adherence and dosing schedule differences (once daily vs multiple daily dosing)
- Tolerance management practices
Timeline and projection: what is the forecast for isosorbide demand?
No quantified projection can be produced without selecting one of the distinct “isosorbide” product categories and defining the forecasting horizon and geography.
Key Takeaways
- “Isosorbide” is not a unique drug identifier for clinical-trials and market analytics. It maps to multiple active ingredients and product classes that behave differently in clinical development, competition, and regulatory listing.
- A complete clinical-trials update, market sizing, and forecast requires the exact formulation entity (e.g., isosorbide mononitrate vs dinitrate; immediate-release vs extended-release) tied to a specific regulatory listing.
FAQs
- Is “isosorbide” the same as isosorbide mononitrate or isosorbide dinitrate?
- Which isosorbide formulations have the most generic competition by country?
- Are there currently any active Phase 3 trials for isosorbide mononitrate or dinitrate?
- Does isosorbide have Orange Book listed patents in the US for specific reference products?
- How do nitrate tolerance and dose scheduling affect real-world use of isosorbide products?
References
- (No sources cited because the provided input does not specify an unambiguous isosorbide drug entity.)
